
    
      The primary purpose of the phase Ib part of this study is to determine the maximum tolerated
      dose(s) (MTD(s)) and/or recommended phase II dose (RP2D) of LEE011 + everolimus + exemestane
      in patients with ER+ Her2- advanced breast cancer. This part of the study will also assess
      safety, tolerability, and PK of the LEE011 + exemestane, LEE011 + everolimus + exemestane
      combinations.

      The Dose Expansion part of the study will evaluate the triple combination of LEE011 +
      everolimus + exemestane and the double combination of LEE011 + exemestane for safety and
      tolerability.
    
  